BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36928090)

  • 1. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
    J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
    Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
    Moldvay J; Tímár J
    Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
    Drosten M; Barbacid M
    Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
    Morel M; Long W
    Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
    Hofmann MH; Gerlach D; Misale S; Petronczki M; Kraut N
    Cancer Discov; 2022 Apr; 12(4):924-937. PubMed ID: 35046095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
    Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
    bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
    Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY
    Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
    Sanclemente M; Francoz S; Esteban-Burgos L; Bousquet-Mur E; Djurec M; Lopez-Casas PP; Hidalgo M; Guerra C; Drosten M; Musteanu M; Barbacid M
    Cancer Cell; 2018 Feb; 33(2):217-228.e4. PubMed ID: 29395869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.